Purui Bio Announces Nearly RMB 100 Million New Round of Financing Led by Xiali-Tai Pharmaceutical, with Lightsource Capital as Financial Advisor

PuriGene Technology (Beijing) Co., Ltd. (“PuriGene”) announced the completion of a new round of financing,This funding round was led by Salubris Pharmaceuticals. Lighthouse Capital served as the financial advisor in this transaction. The proceeds will be used to continuously upgrade the company’s multi-omics data mining system platform and to support the research and development of precision diagnostic products.

Prism Genomics has independently developed a world-class multi-omics data mining and analysis platform, providing pharmaceutical companies with unique, omics data mining-driven novel translational medicine services, and is committed to becoming an “external brain-level” R&D partner for pharmaceutical enterprises. The company is currently the only mature multi-omics data mining and application service provider in China that supports new drug development. By providing customers with key decision support during the drug development process (such as new target assessment, indication selection, discovery of innovative biomarkers, exploration of combination regimens, etc.), as well as central laboratory testing and companion diagnostic development services, Prism Genomics offers one-stop solutions in translational medicine for pharmaceutical companies. Founded by Dr. Ji Xuwo and Professor Liang Han, the company’s clients now include many leading international and domestic enterprises, including top-tier oncology pharmaceutical companies.

Dr. Ji Xuwo, Founder of Purui BenchmarkSalient Pharmaceuticals’ Letter of Appreciation Demonstrates Its Confidence as an Industrial Investor in the Purui Benchmark Team. As a leading enterprise in China’s cardiovascular sector, Salient Pharmaceuticals has established a unique innovative pipeline for chronic diseases, extending into areas such as diabetes and orthopedics. Through this collaboration, we aim to expand our translational medicine services—characterized by multi-omics data mining—into broader fields including chronic disease management, thereby creating greater value.

Duan Feng, General Manager of the Investment Department at Salubris PharmaceuticalsIt is stated that this transaction will help Salubris further enhance its R&D efficiency, identify new pathways to address unmet clinical needs, and accelerate the launch of products for chronic diseases. This is expected to strengthen the company’s comprehensive capabilities in new drug development, provide new avenues for innovative drug research, and align with industry trends and the company’s long-term strategic plan.

Hong Lei, Executive Director of Lightsource Capital“It stated: ‘Leveraging the distinctive advantages of its AIBERT® (multi-omics data mining) platform, Purui Benchmark has entered the new drug R&D sector by integrating robust bioinformatics research capabilities. By combining the most valuable omics data with state-of-the-art artificial intelligence algorithms, it provides pharmaceutical companies with differentiated development strategies for novel drugs amid increasingly fierce competition in China’s innovative drug industry. We are optimistic that Purui Benchmark will evolve into a platform-based company empowering R&D at world-class pharmaceutical enterprises, thereby benefiting patients worldwide.’”

Shenzhen Salubris Pharmaceuticals Co., Ltd. was established in 1998 and listed on the Shenzhen Stock Exchange in 2009 (Stock Code: 002294). It is a comprehensive pharmaceutical group integrating R&D, manufacturing, and sales of pharmaceutical products. With multiple R&D centers established in China and the United States, the company covers the entire industry chain and leverages global innovative resources to study pathogenic mechanisms, explore therapeutic approaches, and develop innovative drugs.

Salubris is dedicated to the cardiovascular and cerebrovascular fields, having established a strategically synergistic product portfolio encompassing chemical drugs, biologics, and medical devices to provide comprehensive solutions for patients. The company is also exploring innovative drugs in areas such as hypoglycemic agents, oncology, orthopedics, nephrology, and anti-infectives, thereby building a system for original drug innovation.

Lighthouse Capital, established in 2014, is a rapidly growing industrial investment bank that serves global enterprises with an international perspective. It is committed to facilitating industrial upgrading and development through capital services and ecosystem empowerment. Its current business scope covers private equity financing advisory, mergers and acquisitions and restructuring, asset management, securities underwriting, and industrial development consulting. Since its inception, Lighthouse Capital has assisted more than 200 companies in the new economy and industrial groups in completing over 330 private financing transactions, with a cumulative transaction value exceeding USD 35 billion. Additionally, it has helped more than 50 companies grow into unicorns in their respective fields.